In the Spotlight: BioVie's (NASDAQ: BIVI) Quest to Tackle Alzheimer's, Parkinson's, and More

Nov. 6, 2023
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) and BIV201 for Refractory Ascites and HRS-AKI. Visit to learn more.

 Read More

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market